Literature DB >> 26058078

ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.

Liem T Nguyen1, Maria S Tretiakova2, Mark R Silvis1, Jared Lucas1, Olga Klezovitch1, Ilsa Coleman1, Hamid Bolouri1, Vassily I Kutyavin1, Colm Morrissey3, Lawrence D True4, Peter S Nelson5, Valeri Vasioukhin6.   

Abstract

The significance of ERG in human prostate cancer is unclear because mouse prostate is resistant to ERG-mediated transformation. We determined that ERG activates the transcriptional program regulated by YAP1 of the Hippo signaling pathway and found that prostate-specific activation of either ERG or YAP1 in mice induces similar transcriptional changes and results in age-related prostate tumors. ERG binds to chromatin regions occupied by TEAD/YAP1 and transactivates Hippo target genes. In addition, in human luminal-type prostate cancer cells, ERG binds to the promoter of YAP1 and is necessary for YAP1 expression. These results provide direct genetic evidence of a causal role for ERG in prostate cancer and reveal a connection between ERG and the Hippo signaling pathway.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26058078      PMCID： PMC4461839          DOI： 10.1016/j.ccell.2015.05.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  46 in total

1.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 2.  Mouse models of prostate cancer.

Authors:  P Sharma; N Schreiber-Agus
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

3.  Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.

Authors:  Jianghua Wang; Yi Cai; Long-Jiang Shao; Javed Siddiqui; Nallasivam Palanisamy; Rile Li; Chengxi Ren; Gustavo Ayala; Michael Ittmann
Journal:  Cancer Res       Date:  2010-12-17       Impact factor: 12.701

4.  YAP1 increases organ size and expands undifferentiated progenitor cells.

Authors:  Fernando D Camargo; Sumita Gokhale; Jonathan B Johnnidis; Dongdong Fu; George W Bell; Rudolf Jaenisch; Thijn R Brummelkamp
Journal:  Curr Biol       Date:  2007-11-01       Impact factor: 10.834

5.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  ETS rearrangements and prostate cancer initiation.

Authors:  Brett S Carver; Jennifer Tran; Zhenbang Chen; Arkaitz Carracedo-Perez; Andrea Alimonti; Caterina Nardella; Anuradha Gopalan; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

8.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

Authors:  Jianghua Wang; Yi Cai; Wendong Yu; Chengxi Ren; David M Spencer; Michael Ittmann
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

9.  TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Authors:  Orla M Casey; Lei Fang; Paul G Hynes; Wassim G Abou-Kheir; Philip L Martin; Heather S Tillman; Gyorgy Petrovics; Hibah O Awwad; Yvona Ward; Ross Lake; Luhua Zhang; Kathleen Kelly
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin.

Authors:  Daniel Nava Rodrigues; Steve Hazell; Susana Miranda; Mateus Crespo; Cyril Fisher; Johann S de Bono; Gerhardt Attard
Journal:  Histopathology       Date:  2014-11-10       Impact factor: 5.087
View more
  54 in total

Review 1.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

2.  ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.

Authors:  Chen-Ying Liu; Tong Yu; Yuji Huang; Long Cui; Wanjin Hong
Journal:  J Biol Chem       Date:  2017-04-13       Impact factor: 5.157

Review 3.  Drug development against the hippo pathway in mesothelioma.

Authors:  Gavitt A Woodard; Yi-Lin Yang; Liang You; David M Jablons
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 4.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Authors:  Min Hwan Kim; Joon Kim
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

5.  Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Authors:  Monika Haemmerle; Morgan L Taylor; Tony Gutschner; Sunila Pradeep; Min Soon Cho; Jianting Sheng; Yasmin M Lyons; Archana S Nagaraja; Robert L Dood; Yunfei Wen; Lingegowda S Mangala; Jean M Hansen; Rajesha Rupaimoole; Kshipra M Gharpure; Cristian Rodriguez-Aguayo; Sun Young Yim; Ju-Seog Lee; Cristina Ivan; Wei Hu; Gabriel Lopez-Berestein; Stephen T Wong; Beth Y Karlan; Douglas A Levine; Jinsong Liu; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Nat Commun       Date:  2017-08-21       Impact factor: 14.919

Review 6.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 7.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

8.  miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance.

Authors:  Y Guo; J Cui; Z Ji; C Cheng; K Zhang; C Zhang; M Chu; Q Zhao; Z Yu; Y Zhang; Y-X Fang; W-Q Gao; H H Zhu
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

9.  Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.

Authors:  Tae-Dong Kim; Fang Jin; Sook Shin; Sangphil Oh; Stan A Lightfoot; Joseph P Grande; Aaron J Johnson; Jan M van Deursen; Jonathan D Wren; Ralf Janknecht
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

10.  α3β1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.

Authors:  Afshin Varzavand; Will Hacker; Deqin Ma; Katherine Gibson-Corley; Maria Hawayek; Omar J Tayh; James A Brown; Michael D Henry; Christopher S Stipp
Journal:  Cancer Res       Date:  2016-09-28       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.